Equities
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.

  • Revenue in EUR (TTM)5.21bn
  • Net income in EUR65.56m
  • Incorporated1987
  • Employees27.58k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
GRF:MCE since
announced
Transaction
value
Prometic Plasma Resources Inc-Donation CenterDeal completed04 Jan 202204 Jan 2022Deal completed-38.92%3.14m
Data delayed at least 15 minutes, as of Dec 09 2022 16:10 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Krka d.d. Novo Mesto1.63bn369.41m3.09bn11.49k7.931.396.721.8911.8711.8752.4467.810.6441.443.50141,729.9014.6011.0717.2813.2455.6357.6822.6616.242.27--0.005456.252.015.926.2623.31-9.8915.41
BB BIOTECH AG-312.62m-878.75m3.26bn----1.17-----15.67-15.67-5.6049.62-0.0868-------24.396.67-26.507.00--99.75--63.36---0.69960.100280.76-146.32---158.57----6.96
Abcam Plc406.94m7.90m3.37bn1.75k428.093.9853.028.280.02960.02961.533.180.3711.856.49200,228.600.7199--0.8403--72.69--1.94--0.982823.460.2401--------------
Dechra Pharmaceuticals plc791.81m67.59m3.54bn2.04k50.094.3520.784.470.53420.53426.266.150.54381.825.60334,872.304.643.555.314.0056.5156.748.547.221.6924.890.330596.3512.1413.674.8617.3948.5015.93
Dottikon ES Holding AG287.21m75.17m3.63bn670.0047.584.6837.9612.625.385.3820.5554.730.31660.46415.14426,878.208.296.739.677.5675.5981.9126.1719.641.78--0.0383--15.0910.6713.3321.7523.13--
Richter Gedeon Vegyeszeti Gyar Nyrt1.82bn583.01m3.86bn12.18k6.621.465.492.131,301.431,301.434,051.995,896.200.60432.163.8461,577,310.0019.557.8722.618.9557.4555.9832.3613.182.53--0.015637.8211.2610.1033.3816.1031.4916.23
Hikma Pharmaceuticals Plc2.42bn328.48m3.89bn8.70k12.431.887.771.611.221.229.028.080.57131.653.45239,517.807.753.809.995.2151.2950.9013.576.611.378.360.414571.439.065.54-2.3222.123.8011.07
Swedish Orphan Biovitrum AB (publ)1.63bn229.63m6.03bn1.56k25.232.4912.883.708.378.3759.3984.680.36241.375.5911,350,870.005.108.456.1810.6174.6676.4114.0821.080.52239.070.28890.001.7624.44-17.4427.3117.53--
Grifols SA5.21bn65.56m6.17bn27.58k105.901.0711.881.190.09420.09427.569.320.27951.308.91224,102.700.74824.230.93475.1536.9044.512.6812.070.90512.920.540126.75-7.624.02-71.29-19.121.49--
BACHEM HOLDING AG504.83m99.33m6.39bn1.66k63.135.6949.0612.671.361.366.8815.070.49181.195.83304,439.309.689.8211.6412.3031.5531.4319.6819.024.0613.640.000663.7625.1816.3046.9122.7218.436.96
Orion Oyj1.32bn350.70m7.09bn3.53k20.187.2618.045.362.492.499.406.921.011.638.28394,217.6026.7318.9431.6323.8264.0659.5226.5219.892.26--0.1812101.61-3.44-0.613-11.87-4.8912.25-0.6537
DiaSorin SpA-100.00bn-100.00bn7.26bn3.35k--------------------------16.63--19.02--67.86--24.99------25.2440.4316.8025.4622.5825.685.59
Recordati Industria Chimica e Farma SpA1.80bn331.04m8.47bn4.30k25.465.1718.994.701.591.598.657.840.52161.665.19418,644.409.5914.3512.0018.1570.1671.3418.3823.931.0811.550.513659.229.066.498.7310.2134.749.46
Ipsen SA3.08bn725.60m8.98bn5.74k12.282.889.312.918.728.8537.0537.150.61472.505.23536,629.5014.509.5319.3113.4682.8281.5023.6014.051.7550.370.192722.4511.6512.4118.8223.422.817.14
Data as of Dec 09 2022. Currency figures normalised to Grifols SA's reporting currency: Euro EUR

Institutional shareholders

15.73%Per cent of shares held by top holders
HolderShares% Held
Capital Research & Management Co. (World Investors)as of 30 Sep 202219.88m4.67%
The Vanguard Group, Inc.as of 31 Oct 20228.10m1.90%
Norges Bank Investment Managementas of 31 Dec 20217.42m1.74%
BlackRock Fund Advisorsas of 03 Nov 20226.54m1.54%
Jupiter Asset Management Ltd.as of 31 Aug 20225.53m1.30%
LGT Capital Partners AG (Investment Management)as of 31 May 20225.01m1.18%
DWS Investment GmbHas of 03 Nov 20224.52m1.06%
BNP Paribas Asset Management France SASas of 31 Oct 20223.65m0.86%
Geode Capital Management LLCas of 01 Dec 20223.26m0.77%
Capital International Ltd.as of 03 Nov 20223.11m0.73%
More ▼
Data from 31 Dec 2021 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.